{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:29:40Z","timestamp":1786685380779,"version":"build-2736575974"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp;amp; Perspec"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>During the past two decades, it has become evident that pharmaceuticals is an emerging environmental problem. In this study, we present the experiences from two Swedish Drug &amp; Therapeutics Committees (DTCs) on how they integrate environmental considerations into their formularies and continuous professional education activities. A cross sectional study was performed describing activities to promote sustainable prescribing conducted during two decades by the DTCs in the Swedish regions of G\u00e4vleborg and V\u00e4sternorrland, along with trends in sales of diclofenac and fluoroquinolones between 2000 and 2024. The two DTCs integrate environmental considerations in their formularies and continuous professional education activities. Further acitivities include monitoring of prescribing, dialogue with water suppliers and pharmacies, as well as information and communication to the general public. The total utilization of diclofenac for systemic use peaked with 127\u2009kg in G\u00e4vleborg and 137\u2009kg in V\u00e4sternorrland in 2011, after which the amounts declined. The topical formulations were mainly sold as over\u2010the\u2010counter and increased until 2016, when it started to decline. The amounts of ciprofloxacin and norfloxacin increased until 2012 when they started to decline. This case study from two Swedish regions illustrates how environmental considerations can be incorporated into the DTC's mission to promote rational and responsible medication use. We believe it may be valuable for different stakeholders to show potential ways in how to promote a more sustainable use of medicines.<\/jats:p>","DOI":"10.1002\/prp2.70279","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:00:11Z","timestamp":1782014411000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Promoting Sustainable Prescribing\u2014A Case Study Presenting Experiences From Two Swedish Drug and Therapeutics Committees"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6710-875X","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Ericsson","sequence":"first","affiliation":[{"name":"G\u00e4vleborg Drug and Therapeutics Committee  G\u00e4vle Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6188-9240","authenticated-orcid":false,"given":"Ulf","family":"Lindahl","sequence":"additional","affiliation":[{"name":"V\u00e4sternorrland Drug and Therapeutics Committee  H\u00e4rn\u00f6sand Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9778-0573","authenticated-orcid":false,"given":"Johanna","family":"Vill\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0326-6137","authenticated-orcid":false,"given":"Marmar","family":"Nekoro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy Uppsala University  Uppsala Sweden"},{"name":"Swedish Medical Products Agency  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-6136","authenticated-orcid":false,"given":"Helena","family":"Ramstr\u00f6m","sequence":"additional","affiliation":[{"name":"Health and Medical Care Administration  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0531-2516","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"The Rational Use of Drugs. WHO Report of the Conference of Experts, Nairobi","author":"World Health Organization (WHO)","year":"1985"},{"key":"e_1_2_10_3_1","volume-title":"Drug and Therapeutics Committees. A Practical Guide","author":"Holloway K.","year":"2003"},{"key":"e_1_2_10_4_1","first-page":"207","article-title":"Drug and Therapeutics Committees: A Swedish Experience","volume":"16","author":"Sj\u00f6qvist F.","year":"2002","journal-title":"WHO Drug Information"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1491-y"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-011-9501-6"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.9.1.65"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00682.x"},{"key":"e_1_2_10_9_1","unstructured":"Lag (1996:1157) om L\u00e4kemedelskommitt\u00e9er (Law on Drug and Therapeutics Committees) accessed September 9 2025 https:\/\/www.riksdagen.se\/sv\/dokument\u2010och\u2010lagar\/dokument\/svensk\u2010forfattningssamling\/lag\u201019961157\u2010om\u2010lakemedelskommitteer_sfs\u20101996\u20101157\/."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050526"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.184374"},{"key":"e_1_2_10_12_1","unstructured":"Strama\u2014The Swedish Strategic Programme Against Antibiotic Resistance accessed September 9 2025 https:\/\/strama.se\/en\/."},{"key":"e_1_2_10_13_1","unstructured":"Folkh\u00e4lsomyndigheten (The Public Health Agency of Sweden). F\u00f6rs\u00e4ljningen av Antibiotika Bromsade in Under 2024(2025) accessed September 19 2025 https:\/\/www.folkhalsomyndigheten.se\/nyheter\u2010och\u2010press\/nyhetsarkiv\/2025\/januari\/forsaljningen\u2010av\u2010antibiotika\u2010bromsade\u2010in\u2010under\u20102024\/."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-445X(98)00112-X"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.1104477"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2016.07.001"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113947119"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/etc.3339"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12302-023-00783-8"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13750-025-00357-6"},{"issue":"6","key":"e_1_2_10_21_1","first-page":"S458","article-title":"Diclofenac Poisoning is Widespread in Declining Vulture Populations Across the Indian Subcontinent","volume":"271","author":"Shultz S.","year":"2004","journal-title":"Proceedings of the Biological Sciences"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aquatox.2004.03.015"},{"key":"e_1_2_10_23_1","unstructured":"Swedish Agency for Marine and Water Management Klassificering och Milj\u00f6kvalitetsnormer Avseende Ytvatten (HVMFS 2019:25)(2019) accessed September 9 2025 https:\/\/www.havochvatten.se\/download\/18.4705beb516f0bcf57ce1c145\/1576576601249\/HVMFS%202019\u201025\u2010ev.pdf."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2021.106436"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2007.07.008"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2021.100381"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riae073"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/etc.5563"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joclim.2021.100079"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanplh.2025.101404"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-008-9260-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02885-1"},{"key":"e_1_2_10_33_1","unstructured":"Health and Medical Care Administration Region Stockholm Sweden Pharmaceuticals and Environment [Database] accessed September 9 2025 https:\/\/janusinfo.se\/beslutsstod\/lakemedelochmiljo\/pharmaceuticalsandenvironment.4.7b57ecc216251fae47487d9a.html."},{"key":"e_1_2_10_34_1","unstructured":"Mistra Pharma Identification and Reduction of Environmental Risks Caused by Human Pharmaceuticals. MistraPharma Research 2008\u20132015 Final Report accessed September 9 2025 https:\/\/mistra.org\/wp\u2010content\/uploads\/2022\/12\/MistraPharma\u2010FinalReport\u20102008\u20102015\u2010ENG.pdf."},{"key":"e_1_2_10_35_1","unstructured":"European Commission Directive of the European Parliament and of the Council Amending Directive 2000\/60\/EC Establishing a Framework for Community Action in the Field of Water Policy Directive 2006\/118\/EC on the Protection of Groundwater Against Pollution and Deterioration and Directive 2008\/105\/EC on Environmental Quality Standards in the Field of Water Policy accessed September 9 2025 https:\/\/environment.ec.europa.eu\/system\/files\/2022\u201010\/Proposal%20for%20a%20Directive%20amending%20the%20Water%20Framework%20Directive%2C%20the%20Groundwater%20Directive%20and%20the%20Environmental%20Quality%20Standards%20Directive.pdf."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg208"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3426"},{"key":"e_1_2_10_38_1","volume-title":"Fluoroquinolone and Quinolone Antibiotics: PRAC Recommends New Restrictions on Use Following Review of Disabling and Potentially Long\u2010Lasting Side Effects","author":"European Medicines Agency","year":"2018"},{"key":"e_1_2_10_39_1","unstructured":"European Medicines Agency PRAC Recommendations on Signals Adopted at the 3\u20136 September 2018 PRAC Meeting accessed September 9 2025 https:\/\/www.ema.europa.eu\/en\/documents\/prac\u2010recommendation\/prac\u2010recommendations\u2010signals\u2010adopted\u20103\u20106\u2010september\u20102018\u2010prac\u2010meeting_en.pdf."},{"key":"e_1_2_10_40_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology ATC Classification Index With DDDs 2024 accessed September 9 2025 https:\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13944"},{"key":"e_1_2_10_42_1","unstructured":"FASS V\u00e5rd accessed September 9 2025 https:\/\/www.fass.se\/LIF\/startpage?userType=0."},{"key":"e_1_2_10_43_1","unstructured":"HSLF\u2010FS 2017:37 Socialstyrelsens F\u00f6reskrifter och Allm\u00e4nna r\u00e5d om Ordination och Hantering av L\u00e4kemedel i H\u00e4lso\u2010 och Sjukv\u00e5rden accessed September 9 2025 https:\/\/www.socialstyrelsen.se\/kunskapsstod\u2010och\u2010regler\/regler\u2010och\u2010riktlinjer\/foreskrifter\u2010och\u2010allmanna\u2010rad\/konsoliderade\u2010foreskrifter\/201737\u2010om\u2010ordination\u2010och\u2010hantering\u2010av\u2010lakemedel\u2010i\u2010halso\u2010\u2010och\u2010sjukvarden\/."},{"key":"e_1_2_10_44_1","unstructured":"The National Agency for Public Procurement (Upphandlingsmyndigheten) Criteria for Tender of Medical Products accessed September 9 2025 https:\/\/www.upphandlingsmyndigheten.se\/en\/criteria\/nursing\u2010and\u2010care\/medicinal\u2010products\/medicinal\u2010products\/."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2010.00141"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104213"},{"key":"e_1_2_10_47_1","unstructured":"Sveriges Apoteksf\u00f6rening Diklofenak Flyttas Bakom Apoteksdisken(2023) accessed September 9 2025 https:\/\/sverigesapoteksforening.se\/diklofenak\u2010flyttas\u2010bakom\u2010apoteksdisken\/."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101430"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1787\/c936f42d-en"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09646-7"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2023.100303"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150704100209"},{"key":"e_1_2_10_53_1","unstructured":"Swedish Dental and Pharmaceutical Benefits Agency (TLV) Tandv\u00e5rds\u2010 och L\u00e4kemedelsf\u00f6rm\u00e5nsverket 2023. 2023 \u00e5rs Uppf\u00f6ljning av Apoteksmarknaden accessed September 9 2025 https:\/\/www.tlv.se\/download\/18.56557acb18a8d1da96d5cbf2\/1695102422977\/2023_uppfoljning_av_apoteksmarknadens_utveckling_860\u20102023.pdf."},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2021.148047"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70279","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70279","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:19:19Z","timestamp":1786684759000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/prp2.70279"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70279","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"2026-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70279"}}